What is OncoLens?
OncoLens operates as a sophisticated AI-enabled digital healthcare platform designed to streamline the multidisciplinary care process for oncology patients. By providing a comprehensive suite of tools for clinical decision support, the platform enables healthcare providers to optimize workflows, enhance biomarker testing, and improve trial matching. Its market footprint is significant, with adoption by over 10% of U.S. cancer centers and 50% of top-tier pharmaceutical companies. The platform serves as a vital bridge between clinical practice and life sciences research, ensuring that patient outcomes are prioritized through coordinated, evidence-based interventions.
How much funding has OncoLens raised?
OncoLens has raised a total of $27.1M across 4 funding rounds:
Angel/Seed
$1.4M
Private Equity
$2.5M
Series A
$7.3M
Series B
$16M
Angel/Seed (2019): $1.4M, investors not publicly disclosed
Private Equity (2020): $2.5M led by Atlanta Technology Angels, BIP Capital, and Robbins Fund
Series A (2021): $7.3M supported by Martin Ventures and BIP Capital
Series B (2024): $16M featuring BIP Capital, SeedtoB Capital, Martin Ventures, and Cross-Border Impact Ventures
Key Investors in OncoLens
Martin Ventures
A healthcare-focused investment firm dedicated to transforming the ecosystem by rewarding providers for achieving superior health outcomes and facilitating the shift toward value-based care.
BIP Capital
A prominent venture investor in the Southeast that provides operational expertise and strategic guidance to help emerging companies maintain a consistent growth trajectory.
SeedtoB Capital
An investment firm specializing in healthcare AI startups, leveraging deep industry expertise to help companies navigate the critical transition from early-stage development to Series B scaling.
What's next for OncoLens?
With the successful completion of this major strategic investment, OncoLens is poised to accelerate its expansion into new clinical markets and further refine its prescriptive AI capabilities. The company's focus will likely shift toward scaling its enterprise-level offerings, deepening its integration with existing health systems, and expanding its reach within the global pharmaceutical research ecosystem. By leveraging its robust data network, OncoLens is well-positioned to lead the next wave of innovation in precision oncology, driving both operational efficiency and improved patient survival rates in an increasingly data-centric healthcare landscape.
See full OncoLens company page
